EICHOR
● Recruiting
Human Embryonic Stem Cell-Derived Cardiomyocyte Therapy for Chronic Ischemic Left Ventricular Dysfunction
Condition: Chronic Ischemic Left Ventricular Dysfunction · Sponsor: Joseph C. Wu
About this study
This clinical study will utilize a new cell therapy approach (Human embryonic stem cells derived cardiomyocytes or hESC-CMs) to improve survival and cardiac function in patients with chronic left ventricular dysfunction secondary to MI (Myocardial Infarction).
This description comes directly from the study's public registry record.
Talk to the study team
Joseph C. Wu, MD, PhD · (650) 736-2246 · joewu@stanford.edu
Evgenios Neofytou, MD · (650) 736-2246 · neofytou@stanford.edu
Always discuss trial participation with your own doctor first.
Locations (1)
| Stanford Hospital and Clinics | Palo Alto, California, United States | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05068674